Aberrant and alternative splicing in cancer

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• Pre-messenger RNA (mRNA) splicing is a fundamental nuclear process essential for gene expression.
• Errors in splicing, including exon skipping and alternative splicing, are increasingly recognized as significant contributors to oncogenesis.
• These splicing aberrations can lead to truncated or non-functional tumor suppressor proteins, driving cancer initiation and progression.

Purpose of the Study:

• To highlight the role of pre-mRNA splicing errors in cancer development.
• To discuss cancer-specific alternative splicing events and their impact on protein function.
• To explore the diagnostic and therapeutic potential of targeting alternative splicing in cancer.

Main Methods:

• Review of existing literature on splicing errors and cancer.
• Analysis of studies reporting cancer-specific alternative splicing events.
• Examination of current diagnostic and therapeutic strategies targeting alternative splicing.

Main Results:

• Intronic splice site mutations in tumor suppressor genes can cause exon skipping, leading to protein truncation.
• Numerous studies have identified cancer-specific alternative splicing events independent of genomic mutations.
• Affected proteins encompass critical cancer-related molecules like transcription factors and cell signaling components.

Conclusions:

• Alternative splicing is a significant factor in cancer biology, often promoting tumorigenesis.
• Antibodies targeting alternatively spliced products show promise in clinical trials.
• Alternative splicing represents a viable target for novel cancer gene therapies and diagnostics.